2. Signaling Pathways
  3. GPCR/G Protein
  4. GLP Receptor

GLP Receptor

GLP Receptor

The GLP receptors contain two family members, GLP-1 receptor (GLP1R, or GLP-1R) and GLP-2 receptor (GLP2R or GLP-1R), activated by the glucagon-like peptides (GLPs). GLPs are s secreted by intestinal cells; causes insulin release; inhibits glucagon secretion, appetite, and energy intake; and delays gastric emptying because GLP receptors are located on the gut, pancreas, brainstem, hypothalamus, and vagal-afferent nerves. GLP-1 has only one known receptor, GLP1R, and regulates gut motility, appetite, islet function, and glucose homeostasis, whereas GLP-2, the agonist of GLP2R, enhances intestinal nutrient absorption. GLP-1R agonists are used to treat diabetes and obesity, and a GLP-2R agonist is approved to treat short bowel syndrome. An investigation of the actions of GLP receptor activation on gallbladder motility has demonstrated that GLP-2 receptor activation increases gallbladder volume in vivo and decreases spontaneous activity in GBSM bundles ex vivo. Like the inhibitory transmitters, which elicit their actions via an adenylate cyclase-protein kinase A-KATP channel pathway, the GLP-2 receptor signals through this same pathway.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P1445
    HAEGTFTSDVSSYLE
    		98.16%
    HAEGTFTSDVSSYLE is a polypeptide from patent CN 102920658 B. GLP-I analog contains the sequence.
    HAEGTFTSDVSSYLE
  • HY-P990989
    Efmedaglutide alfa
    HY-P990989 is an GLP-1 receptor-targeting Fusion Protein.
    Efmedaglutide alfa
  • HY-P990990
    Efsubaglutide alfa
    HY-P990990 is an GLP-1 receptor-targeting Fusion Protein.
    Efsubaglutide alfa
  • HY-P990967
    Sonefpeglutide
    Sonefpeglutide is a long-acting glucagon-like peptide 2 (GLP-2) analog.
    Sonefpeglutide
  • HY-P5161
    FC382K10W15
    		Agonist
    FC382K10W15 is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 can be used in type 2 diabetes research.
    FC382K10W15
  • HY-P10318
    SHR-2042
    		Antagonist
    SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency.
    SHR-2042
  • HY-143312C
    (S)-V-0219
    		Modulator
    (S)-V-0219 is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 is orally active and ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice.
    (S)-V-0219
  • HY-162306
    GLP-1R agonist 18
    		Agonist
    GLP-1R agonist 18 (example 117) is an agonist for GLP-1R with an EC50 of 0.044 nM.
    GLP-1R agonist 18
  • HY-P10591
    Olatorepatide
    		Agonist
    Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect.
    Olatorepatide
  • HY-147628
    GLP-1R agonist 15
    		Agonist
    GLP-1R agonist 15 (Compound 101) is a GLP-1 receptor agonist.
    GLP-1R agonist 15
  • HY-162436
    GLP-1R agonist 21
    		Agonist
    GLP-1R agonist 21 (Compound I-134) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC50 of 0.0104 nM.
    GLP-1R agonist 21
  • HY-P5161A
    FC382K10W15 TFA
    		Agonist
    FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research.
    FC382K10W15 TFA
  • HY-170511
    GLP-1 receptor agonist 15
    		Agonist
    GLP-1 receptor agonist 15 (Example 4) is a GLP receptor agonist with an EC50 of 0.74 nM. The IC50 for the hERG potassium ion channel is 10.1 μM. GLP-1 receptor agonist 15 can be used for research in the field of diabetes.
    GLP-1 receptor agonist 15
  • HY-160031
    GLP-1R agonist 19
    		Agonist
    GLP-1R agonist 19 (M3190) is a potent and selective GLP-1R agonist. GLP-1R agonist 19 has excellent plasma stability, liver microsomal stability, and low hERG toxicity.
    GLP-1R agonist 19
  • HY-162435
    GLP-1R agonist 20
    		Agonist
    GLP-1R agonist 20 (Compound I-132) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC50 of 0.0162 nM.
    GLP-1R agonist 20
  • HY-P10327
    PP18
    		Agonist
    PP18 is a novel OXM-based dual GLP-1 and glucagon receptor agonist with EC50 values of 0.487 nM target hGLP-1R and 0.188 nM target hGcgR.
    PP18
  • HY-143312B
    (R)-V-0219
    		Modulator
    (R)-V-0219 is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (R)-V-0219 activates calcium fluxes in HEK cells stably expressing hGLP-1R.
    (R)-V-0219
  • HY-120828
    Albenatide
    		Agonist
    Albenatide (CJC 1134PC) is a modified Exendin-4 (HY-13443) analogue conjugated to human recombinant albumin (HRA) in vitro to form a long-acting DPP-4-resistant GLP-1R agonist. Albenatide covalently binds through a low-molecular chemical linker (cys-C13H19O6N3-lys) to the cysteine residue in position 34 of HRA. Albenatide increases cyclic AMP (cAMP) production in vitro. Albenatide reduces glucose excursions, food intake, gastric emptying in wild-type mice and improves glucose tolerance and reduces body weight in high-fat diet mice.
    Albenatide
  • HY-147629
    GLP-1R agonist 16
    		Agonist
    GLP-1R agonist 16 (Compound 115a) is a GLP-1 receptor agonist with an EC50 of 0.15 nM.
    GLP-1R agonist 16
  • HY-147627
    GLP-1R agonist 14
    		Agonist
    GLP-1R agonist 14 (Compound 14) is a GLP-1 receptor agonist with an EC50 of 0-20 nM against h-GLP-1.
    GLP-1R agonist 14
Cat. No. Product Name / Synonyms Application Reactivity